Shigeoka, Y., Matsumoto, S. and Shimizu, E. (2009) Synergistic Cell Growth Inhibition by the Combination of Amrubicin and Akt-Suppressing Tyrosine Kinase Inhibitors in Small Cell Lung Cancer Cells: Implication of c-Src and Its
179 Limited stage small cell lung cancer (LS SCLC) – South East Wales experienceT-cell regulatorsImmunohistochemistryBladder cancerOutcomesPrognosisSurvivalIntroduction: The promise of improved survival outcomes and recent changes to NICE lung cancer guidance have prompted the introduction of concurrent ...
The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years.A systematic search was conducted for single technology appraisals of NSCLC...
1) person small cell lung cancer 人小细胞肺癌 1. Inhibition effect of Brucea Javanice soft capsule on person small cell lung cancer LTEPSML transplanted to nude mouse; 鸦胆子油软胶囊对裸鼠移植人小细胞肺癌LTEP-SML抑瘤作用 更多例句>> 2) Human non-small cell lung carcinoma cell line H446...
Looking past this immediate timeframe of a few years, I’m particularly excited about cellular therapeutics against extensive-stage small cell lung cancer. I would highlight as the 2 targets with most immediate promise, DLL3 and GD2. Looking further down the road than that, I’m impressed by...
Lung cancer (non-small-cell, first line) - gefitinib Guidance TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer - NICE 被引量: 0发表: 0年 Lung cancer (non-small cell) - erlotinib & gefitinib (post chemotherapy) (rev TA162, TA175)...
Background Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, and surgery is the preferred treatment for patients. The National Health Service established Primary Care Trusts (PCTs) in 2002 to manage local health needs. We investigate whether PCTs with a low...
EP: 5.Overview of Frontline Treatment Options in Small Cell Lung Cancer EP: 6.Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting? EP: 7.Overview of Second-Line Treatment Options in SCLC Now Viewing EP: 8.Clinical Data With Lurbinectedin in Small Cell Lun...
To evaluate the feasibility of interferon γ (IFNγ) as an adjunct to chemotherapy in advanced non-small-cell lung cancer (NSCLC). Methods: A total of 32 patients were recruited and received 25mg/m 2 cisplatin and 100mg/m 2 etoposide on days 8, 10 and 12 every 3 weeks for a total ...
Patients with non-small cell lung cancer, especially adenocarcinomas, harbour at least one oncogenic driver mutation that can potentially be a target for therapy. Treatments of these oncogene-addicted tumours, such as the use of tyrosine kinase inhibitors (TKIs) of mutated epidermal growth factor rec...